Status:
COMPLETED
Study Evaluating Bifeprunox in Bipolar Depression
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Collaborating Sponsors:
Solvay Pharmaceuticals
Conditions:
Bipolar Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of bipolar disorder
- Experiencing a depressive episode
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
434 Patients enrolled
Trial Details
Trial ID
NCT00134459
Start Date
June 1 2005
End Date
May 1 2006
Last Update
February 15 2013
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35216
2
Beverly Hills, California, United States, 90210
3
National City, California, United States, 91950
4
Stanford, California, United States, 94305